ClinicResearch Article | DOI: https://doi.org/10.31579/2835-8295/021
Neutrophil-to-lymphocyte Ratio (NLR) as an Index of Response to Treatment in Patients with Hepatocellular Carcinoma after Receiving Trans-arterial Chemoembolization (TACE)
- Mohammad Taher 1*
- Neda Shayegan 1
- Niloofar Ayoobi 2
- Esmaeil Mohammadi 2
- Hajir Saberi 3
- Faeze Salahshour 2,3,4
- Forough Alborzi 1
- Nahid Sadighi 2
1 Division of Gastroenterology & Hepatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Department of Radiology, Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran
3 Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Liver Transplantation Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Mohammad, Taher Division of Gastroenterology & Hepatology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Citation: Mohammad Taher, Neda Shayegan, Niloofar Ayoobi, Esmaeil Mohammadi, Hajir Saberi, et. all, (2023), Neutrophil-to-lymphocyte Ratio (NLR) as an Index of Response to Treatment in Patients with Hepatocellular Carcinoma after Receiving Trans-arterial Chemoembolization (TACE), International Journal of Clinical Reports and Studies, 2(3); DOI:10.31579/2835-8295/021
Copyright: © 2023, Mohammad Taher. This is an open-access artic le distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received: 13 May 2023 | Accepted: 29 May 2023 | Published: 07 June 2023
Keywords: hepatocellular carcinoma (HCC); trans-arterial chemoembolization (TACE); neutrophil- to-lymphocyte ratio (NLR); liver transplantation; prognostics
Abstract
Background: Trans-arterial chemoembolization (TACE) is commonly used for patients with large, un-resectable tumors or bridge therapy in patients with hepatocellular carcinoma (HCC) prior to liver transplantation. We evaluated the response to TACE treatment in patients with hepatocellular carcinoma according to modified RECIST criteria and determined the prognostic value of neutrophil-to-lymphocyte ratio (NLR). Methods: Patients with definitive diagnosis of HCC referred for TACE were studied. The response rate to TACE treatment was assessed based on dynamic MRI 28-days after treatment according to modified RECIST. The NLR value was calculated and its prognostic value was evaluated to predict the response to treatment.
Results:
Forty patients with HCC who underwent TACE were included in the study. The response to TACE treatment in included patients was: complete response (CR) in 6 patients (15%), partial response (PR) in 16 patients (40%) and stable disease (SD) in 18 patients (45%). No progressive disease (PD) was found. Responders (CR+PR) were 22 (55%) cases. The mean NLR after treatment in the non-responder group was significantly higher than the responder group (4.2 vs 2.4, P- value=0.026). NLR values greater than 2.6 after treatment had a sensitivity of 70.6% and a specificity of 77.3% in the diagnosis of non-responders with an Area Under the Curve of 0.73 [95% confidence interval 0.58–0.89], P-value=0.011).
Conclusion:
Compared to responders, higher levels of NLR after treatment were observed in the non-responder group. NLR level more than 2.6 after treatment is believed to be able to discriminate non-responders as a moderate prognostication tool.
References
- Bosetti, C., F. Turati, and C. La Vecchia, Hepatocellular carcinoma epidemiology. Best practice & research Clinical gastroenterology, 2014. 28(5): p. 753-770.
View at Publisher | View at Google Scholar - Fattahi, N., et al., Hepatocellular carcinoma incidence at national and provincial levels in Iran from 2000 to 2016: A meta-regression analysis. Plos one, 2021. 16(1): p. e0245468.
View at Publisher | View at Google Scholar - Bertuccio, P., et al., Global trends and predictions in hepatocellular carcinoma mortality. Journal of Hepatology, 2017. 67(2): p. 302-309.
View at Publisher | View at Google Scholar - Aminorroaya, A., et al., Burden of non-communicable diseases in Iran: past, present, and future. Journal of Diabetes & Metabolic Disorders, 2020: p. 1-7.
View at Publisher | View at Google Scholar - Llovet, J.M., C. Brú, and J. Bruix. Prognosis of hepatocellular carcinoma: the BCLC staging classification. in Seminars in liver disease. 1999. © 1999 by Thieme Medical Publishers, Inc
View at Publisher | View at Google Scholar - Sergio, A., et al., Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. American Journal of Gastroenterology, 2008. 103(4): p. 914-921.
View at Publisher | View at Google Scholar
